Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The Momentous Standard
Tirzepatide produces substantial weight loss, 7-13 kg in clinical trials, through potent appetite suppression, delayed gastric emptying, and direct effects on fat metabolism through GIP receptor activation
As a dual GLP-1/GIP receptor agonist, this therapy is formulated for sublingual use under the supervision of a licensed healthcare provider
Inositol prevents fat deposition by stabilising cell membranes and supporting insulin signalling pathways that regulate glucose and lipid metabolism
6 CT-868, an investigational, once-daily, subcutaneously injected dual GLP-1/GIP receptor agonist currently in Phase II with the potential to be a first in class treatment for glycaemic control as an adjunct to insulin in patients living with type 1 diabetes
Here for You Every Day Nature Made is a partner on your health journey, making it easier for you to care for yourself daily
